Syncona Share News (SYNC)
SYNC Share
SYNC Share
SYNC Share
SYNC Share
SYNC
SYNC Share
SYNC Level 2
SYNC Live
SYNC Broker
SYNC Directors
SYNC Financial
SYNC
SYNC Short
SYNC
Last checked at -
To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreMon, 10th Aug 2009 09:56
Syncona Ltd - London-based life science investor owns a diversified portfolio of companies spanning across clinical stages - Chair & Chief Executive Officer Chris Hollowood buys 89,588 shares at average price of GBP1.12, worth GBP99,980, in London on Monday.
Read more(Sharecast News) - Life science investor Syncona announced the addition of two new oncology companies to its portfolio on Thursday.
Read more(Alliance News) - Syncona Ltd on Thursday offered up a resilient set of annual results, swinging to profit after a challenging year thanks in part to the strength of its life sciences portfolio.
Read more(Alliance News) - Syncona Ltd on Monday said it will provide further funding to a newly formed firm created after one of its portfolio companies acquired another.
Read more| Friday 14 June | |
| Tesco PLC | Trading Statement |
| Monday 17 June | |
| Monks Investment Trust PLC | Full Year Results |
| Tuesday 18 June | |
| Ashtead Group PLC | Full Year Results |
| Global Smaller Cos Trust PLC | Full Year Results |
| Intercede Group PLC | Full Year Results |
| Oxford BioDynamics PLC | Half Year Results |
| Tatton Asset Management PLC | Full Year Results |
| Telecom Plus PLC | Full Year Results |
| Wednesday 19 June | |
| Berkeley Group Holdings | Full Year Results |
| NextEnergy Solar Fund Ltd | Full Year Results |
| Schroder European Real Estate Investment Trust PLC | Half Year Results |
| Speedy Hire PLC | Full Year Results |
| Severfield PLC | Full Year Results |
| Young & Co's Brewery PLC | Full Year Results |
| Thursday 20 June | |
| Alpha Financial Markets Consulting PLC | Full Year Results |
| Atrato Onsite Energy PLC | Half Year Results |
| CMC Markets PLC | Full Year Results |
| Cordiant Digital Infrastructure Ltd | Full Year Results |
| DS Smith PLC | Full Year Results |
| Syncona Ltd | Full Year Results |
| Urban Logistics REIT PLC | Full Year Results |
| XPS Pensions Group PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.
Read moreSyncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.
Read more(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
Read more(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.
Read moreSyncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.
Read more(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.
Read moreSyncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.
Read more(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.
Read more(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.
Read more
Last checked at